Fritextsökning
Innehållstyper
-
GSK acquires oncology research company
GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.
-
Sustainability at Festo
On the Way to the Net Zero Era - New Sustainability Report published
-
Kennedy-rådgivare vill stoppa kombovaccin för barn under fyra
Barnvaccineringen i USA är under omprövning. På torsdagen beslutade CDC:s rådgivande vaccinkommitté (ACIP) att stoppa användningen av ett av landets viktigaste ...
-
Ny rapport: Små bolag lyfter svensk läkemedelsutveckling
Sveriges läkemedelsforskning fortsätter att gå starkt framåt, enligt en ny rapport från Sweden Bio. Landets projekt blir både fler och vassare – med småbolagen i spetsen.
-
Allogene discontinues investigational antibody following patient death
U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...
-
Galenica AB
-
Medicon Village Science Park
-
Large study on milk: Risky for women but not for men
The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...
-
Investigations against AstraZeneca: ”Chinese interests may be behind them”
Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.
-
Mercodia AB
-
Lund University’s record-breaking recruitment – attracting researchers from around the world
The Swedish university is launching its largest international recruitment effort ever, aiming to hire 25 researchers globally, including several in the medical field.
-
Quality assurance for research and development of medical devices
Overcome the hurdles of research, development, and QA lab environments within the regulated medical technology industry.
-
Your solution for right part positioning
ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.
-
Björn Arvidsson: ”We must raise our gaze to find the answers of the future”
A system approach isn't just about understanding complexity – it's about making better decisions. By seeing ourselves as part of larger systems, we can better a...
-
Bio Europe to Stockholm – ”The Swedish ecosystem is now taking the opportunity”
globally," says Anna Redwood from Business Sweden.
-
Explore the possibilities of the new ZEISS METROTOM 800 320 kV
Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.
-
Life science trends 2025 – The economy
Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...
-
Developing rapid diagnostics for sepsis – “Every hour counts”
Finding the right antibiotic in the right dose – with an ultra-fast analysis method. Gradientech's product solution is currently used in routine diagnostics at ...
-
Första läkemedlet mot förlossningsdepression får grönt ljus i EU
EU-kommissionen har för första gången godkänt ett läkemedel mot förlossningsdepression, närmare bestämt amerikanska Biogens Zurzuvae.
-
Discover the new ZEISS Axioscan 7 clinical
Your digital slide scanner for diagnostics & clinical research.
-
Tre chefsrockader i CTR-koncernen
Forskningskoncernen Center for Translational Research (CTR) genomför flera skiften på ledande positioner. Flera av bolagen inom gruppen får nu nya chefer.
-
Så blir svenska paviljongen vid Bio-Europe
Jättekonferensen Bio-Europe med över 5 000 deltagare äger i år för första gången rum i Stockholm – och svensk life science samlar styrkorna.
-
Agreement in the EU on eight years of data exclusivity for new medicines
New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...
-
The race between new alzheimer’s drugs Kisunla and Leqembi heats up
Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...